COVID-19 Crisis: How Can Plant Biotechnology Help?

Overview

Journal Plants (Basel)

Date 2021 Mar 6

PMID 33673316

Citations 5

Authors

Md Jahidul Islam Shohag

Farhana Zerin Khan

Lin Tang

YanYan Wei

Zhenli He

Xiaoe Yang

Affiliations

Soon will be listed here.

Abstract

The emergence of the COVID-19 pandemic has led to significant public health crisis all over the world. The rapid spreading nature and high mortality rate of COVID-19 places a huge pressure on scientists to develop effective diagnostics and therapeutics to control the pandemic. Some scientists working on plant biotechnology together with commercial enterprises for the emergency manufacturing of diagnostics and therapeutics have aimed to fulfill the rapid demand for SARS-CoV-2 protein antigen and antibody through a rapid, scalable technology known as transient/stable expression in plants. Plant biotechnology using transient/stable expression offers a rapid solution to address this crisis through the production of low-cost diagnostics, antiviral drugs, immunotherapy, and vaccines. Transient/stable expression technology for manufacturing plant-based biopharmaceuticals is already established at commercial scale. Here, current opinions regarding how plant biotechnology can help fight against COVID-19 through the production of low-cost diagnostics and therapeutics are discussed.

Citing Articles

Clinical and experimental bacteriophage studies: Recommendations for possible approaches for standing against SARS-CoV-2.

Shahin K, Zhang L, Mehraban M, Collard J, Hedayatkhah A, Mansoorianfar M Microb Pathog. 2022; 164:105442.

PMID: 35151823 PMC: 8830156. DOI: 10.1016/j.micpath.2022.105442.

Global Innovation Trends for Plant-Based Vaccines Production: A Patent Analysis.

Frisio D, Ventura V Plants (Basel). 2021; 10(12).

PMID: 34961028 PMC: 8709171. DOI: 10.3390/plants10122558.

Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines.

Maharjan P, Choe S Vaccines (Basel). 2021; 9(9).

PMID: 34579229 PMC: 8473425. DOI: 10.3390/vaccines9090992.

Mass Production of Virus-Like Particles Using Chloroplast Genetic Engineering for Highly Immunogenic Oral Vaccine Against Fish Disease.

Nakahira Y, Mizuno K, Yamashita H, Tsuchikura M, Takeuchi K, Shiina T Front Plant Sci. 2021; 12:717952.

PMID: 34497627 PMC: 8419230. DOI: 10.3389/fpls.2021.717952.

Hairy Roots of spp. () as Promising Producers of Antiviral Flavones.

Stepanova A, Soloveva A, Malunova M, Salamaikina S, Panov Y, Lelishentsev A Molecules. 2021; 26(13).

PMID: 34199058 PMC: 8271535. DOI: 10.3390/molecules26133927.

References

Sexton A, Harman S, Shattock R, Ma J . Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J. 2009; 23(10):3590-600. DOI: 10.1096/fj.09-131995. View

Rademacher T, Sack M, Arcalis E, Stadlmann J, Balzer S, Altmann F . Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant Biotechnol J. 2007; 6(2):189-201. DOI: 10.1111/j.1467-7652.2007.00306.x. View

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J . Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16):1582-1589. PMC: 7101507. DOI: 10.1001/jama.2020.4783. View

Gleba Y, Tuse D, Giritch A . Plant viral vectors for delivery by Agrobacterium. Curr Top Microbiol Immunol. 2013; 375:155-92. DOI: 10.1007/82_2013_352. View

OKeefe B, Murad A, Vianna G, Ramessar K, Saucedo C, Wilson J . Engineering soya bean seeds as a scalable platform to produce cyanovirin-N, a non-ARV microbicide against HIV. Plant Biotechnol J. 2015; 13(7):884-92. PMC: 4529388. DOI: 10.1111/pbi.12309. View

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J . Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020; 117(17):9490-9496. PMC: 7196837. DOI: 10.1073/pnas.2004168117. View

King D, Montague N, Ebert K, Reid S, Dukes J, Schadlich L . Development of a novel recombinant encapsidated RNA particle: evaluation as an internal control for diagnostic RT-PCR. J Virol Methods. 2007; 146(1-2):218-25. DOI: 10.1016/j.jviromet.2007.07.002. View

Hiatt A, Cafferkey R, Bowdish K . Production of antibodies in transgenic plants. Nature. 1989; 342(6245):76-8. DOI: 10.1038/342076a0. View

Buyel J, Fischer R . Predictive models for transient protein expression in tobacco (Nicotiana tabacum L.) can optimize process time, yield, and downstream costs. Biotechnol Bioeng. 2012; 109(10):2575-88. DOI: 10.1002/bit.24523. View

10.

Ma J, Drossard J, Lewis D, Altmann F, Boyle J, Christou P . Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. Plant Biotechnol J. 2015; 13(8):1106-20. DOI: 10.1111/pbi.12416. View

11.

Sexton A, Drake P, Mahmood N, Harman S, Shattock R, Ma J . Transgenic plant production of Cyanovirin-N, an HIV microbicide. FASEB J. 2005; 20(2):356-8. DOI: 10.1096/fj.05-4742fje. View

12.

Barton C, Kouokam J, Lasnik A, Foreman O, Cambon A, Brock G . Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother. 2013; 58(1):120-7. PMC: 3910741. DOI: 10.1128/AAC.01407-13. View

13.

OKeefe B, Giomarelli B, Barnard D, Shenoy S, Chan P, McMahon J . Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol. 2009; 84(5):2511-21. PMC: 2820936. DOI: 10.1128/JVI.02322-09. View

14.

Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti J . Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514(7520):47-53. PMC: 4214273. DOI: 10.1038/nature13777. View

15.

Shang W, Yang Y, Rao Y, Rao X . The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. NPJ Vaccines. 2020; 5(1):18. PMC: 7060195. DOI: 10.1038/s41541-020-0170-0. View

16.

Garrison A, Giomarelli B, Lear-Rooney C, Saucedo C, Yellayi S, Krumpe L . The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Antiviral Res. 2014; 112:1-7. PMC: 4258435. DOI: 10.1016/j.antiviral.2014.09.012. View

17.

Sack M, Rademacher T, Spiegel H, Boes A, Hellwig S, Drossard J . From gene to harvest: insights into upstream process development for the GMP production of a monoclonal antibody in transgenic tobacco plants. Plant Biotechnol J. 2015; 13(8):1094-105. DOI: 10.1111/pbi.12438. View

18.

OKeefe B, Vojdani F, Buffa V, Shattock R, Montefiori D, Bakke J . Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A. 2009; 106(15):6099-104. PMC: 2662964. DOI: 10.1073/pnas.0901506106. View

19.

Irwin K, Renzette N, Kowalik T, Jensen J . Antiviral drug resistance as an adaptive process. Virus Evol. 2017; 2(1):vew014. PMC: 5499642. DOI: 10.1093/ve/vew014. View

20.

Hiatt A, Pauly M, Whaley K, Qiu X, Kobinger G, Zeitlin L . The emergence of antibody therapies for Ebola. Hum Antibodies. 2016; 23(3-4):49-56. DOI: 10.3233/HAB-150284. View